John A. Orwin - 06 Jan 2026 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Role
Director
Signature
/s/ Eric Loumeau, Attorney-in-Fact
Issuer symbol
ANAB
Transactions as of
06 Jan 2026
Net transactions value
$0
Form type
4
Filing time
08 Jan 2026, 16:02:10 UTC
Previous filing
17 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Orwin John A Director C/O ANAPTYSBIO, INC., 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO /s/ Eric Loumeau, Attorney-in-Fact 08 Jan 2026 0001477384

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Stock Option (right to buy) Award $0 +8,250 $0.000000 8,250 06 Jan 2026 Common Stock 8,250 $43.91 Direct F1
transaction ANAB Restricted Stock Unit Award $0 +6,000 $0.000000 6,000 06 Jan 2026 Common Stock 6,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F3 The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.